Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 14/20 | 0.65 |
| ▸ | PRKD3 known ✓ | O94806 | 3/20 | 0.65 |
| ▸ | PRKCD known ✓ | Q05655 | 3/20 | 0.65 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.65 |
| ▸ | CDK6 known ✓ | Q00534 | 4/20 | 0.63 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.57 |
| ▸ | PRKCA known ✓ | P17252 | 2/20 | 0.57 |
| ▸ | PRKCQ known ✓ | Q04759 | 2/20 | 0.57 |
| ▸ | ACVR1 known ✓ | Q04771 | 2/20 | 0.57 |
| ▸ | ALK known ✓ | Q9UM73 | 2/20 | 0.57 |
| ▸ | JAK2 known ✓ | O60674 | 1/20 | 0.57 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.57 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.57 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.57 |
| ▸ | PRKCG known ✓ | P05129 | 1/20 | 0.57 |
| ▸ | PRKCB known ✓ | P05771 | 1/20 | 0.57 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.57 |
| ▸ | CSF1R known ✓ | P07333 | 1/20 | 0.57 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 0.57 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15636652 | 1.00 | CDK4 (0.65) | CDK4CDK1CDK9GSK3BPRKD3 | |
| SCHEMBL7829623 | 0.99 | CDK4 (0.64) | CDK4CDK1CDK9GSK3BPRKD3 | |
| SCHEMBL4585801 | 0.99 | CDK4 (0.64) | CDK4CDK1CDK9GSK3BPRKD3 | |
| SCHEMBL5735816 | 0.88 | CDK4 (0.53) | CDK4CDK1CDK9GSK3BPRKD3 | |
| SCHEMBL23683032 | 0.87 | CDK4 (0.75) | CDK4CDK1CDK9GSK3BPRKD3 | |
| SCHEMBL20181812 | 0.87 | CDK4 (0.75) | CDK4CDK1CDK9GSK3BPRKD3 | |
| SCHEMBL24669074 | 0.86 | CDK4 (0.74) | CDK4CDK1CDK9GSK3BPRKD3 | |
| SCHEMBL22580714 | 0.84 | CDK4 (0.67) | CDK4CDK1CDK9GSK3BPRKD3 | |
| SCHEMBL8821026 | 0.82 | CDK4 (0.60) | CDK4CDK1CDK9GSK3BPRKD3 | |
| Hydrochloric Acid SCHEMBL6120022 | 0.82 | CDK4 (0.62) | CDK4CDK1CDK9GSK3BPRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021144657-A1 | COMBINATION COMPRISING A TIM-3 INHIBITOR AND A HYPOMETHYLATING AGENT FOR USE IN TREATING MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA | NOVARTIS AG (CH) | 2021-07-22 | — | — | WO | disclosed |
| WO-2021123902-A1 | COMBINATION OF ANTI TIM-3 ANTIBODY MBG453 AND ANTI TGF-BETA ANTIBODY NIS793, WITH OR WITHOUT DECITABINE OR THE ANTI PD-1 ANTIBODY SPARTALIZUMAB, FOR TREATING MYELOFIBROSIS AND MYELODYSPLASTIC SYNDROME | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| EP-2086323-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | University Of Maryland, Baltimore (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1954284-A1 | METHOD OF TREATING CANCERS WITH SAHA AND PEMETREXED | Merck and Co., Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1947936-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING CANCER | Merck and Co., Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008057456-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING MULTIPLE MYELOMA | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007056135-A1 | METHOD OF TREATING CANCERS WITH SAHA AND PEMETREXED | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056232-A2 | METHODS OF USING SAHA AND BORTEZOMIB FOR TREATING CANCER | MERCK & CO., INC. (US) | 2007-05-18 | — | — | WO | disclosed |